lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
293 rows where filing_period = "third_quarter", filing_year = 2023 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3041761 | NORIDIAN MUTUAL INSURANCE COMPANY c5ef4861-5d28-4527-83b0-cf1099a2e8d0 | 3T | NORIDIAN MUTUAL INSURANCE COMPANY | 6473 | NORIDIAN MUTUAL INSURANCE COMPANY | 2023 | third_quarter | PHA | INSULIN Act: Insulin Out of Pocket Charges S. 150 - Affordable Prescriptions for Patients Act of 2023 | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2023-08-14T13:04:15-04:00 | ||
| 3044446 | STONINGTON GLOBAL 82ef916b-1266-4094-80ca-bb9985cadde2 | 3T | STONINGTON GLOBAL | 401105189 | SORRENTO THERAPEUTICS, INC. | 2023 | third_quarter | PHA | Promoting non-opioid pain management alternatives. | Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 0 | 1 | 2023-10-03T14:11:36-04:00 | ||
| 3044662 | 2359 STRATEGIES 176c568f-4c61-4d23-a80e-fa1a6ed97aec | Q3 | 2359 STRATEGIES | 401106114 | TRAVERE THERAPEUTICS | 2023 | third_quarter | PHA | Orphan Drug Act | HOUSE OF REPRESENTATIVES,SENATE | 22500 | 0 | 0 | 2023-10-04T10:43:57-04:00 | |
| 3044714 | WATKINS & EAGER PLLC b915aaef-b8fc-42dc-bebf-12f93c1b2adf | Q3 | WATKINS & EAGER PLLC | 401104403 | ZYNERBA PHARMACEUTICALS, INC. | 2023 | third_quarter | PHA | Encourage Members to act favorably on matters of importance to Zynerba at their direction; Trial for medication that could help individuals with Fragile X Syndrome. | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2023-10-04T11:16:34-04:00 | |
| 3044785 | AMERICAN COLLEGE OF CLINICAL PHARMACY 82c25e29-3255-4516-9a33-602545b2ebf9 | Q3 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2023 | third_quarter | PHA | Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. | HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2023-10-04T14:08:32-04:00 | |
| 3045001 | PENN AVENUE PARTNERS 577158e9-5468-4f64-bb01-7400828fa42b | Q3 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2023 | third_quarter | PHA | Regulatory and legislative issues impacting Alkermes. Appropriations. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-04T20:18:02-04:00 | |
| 3045049 | PENN AVENUE PARTNERS 22fe6e65-2e21-4ae8-a484-08f2789d5514 | Q3 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2023 | third_quarter | PHA | Pharmacy benefit related issues. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 90000 | 0 | 0 | 2023-10-05T07:09:10-04:00 | |
| 3045389 | MCDERMOTT+ LLC 818c5795-b79f-4960-8db5-36cade838292 | Q3 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2023 | third_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-06T10:04:06-04:00 | |
| 3045519 | THE MADISON GROUP 65c252ed-4f63-48d7-bf9d-5c27286a0c94 | Q3 | THE MADISON GROUP | 284050 | WALGREEN CO. | 2023 | third_quarter | PHA | Issues pertaining to the retail pharmacy industry, access to and delivery of COVID-19 vaccinations and pharmacy benefit managers (PBMs). H.R. 1770, the Equitable Community Access to Pharmacist Services Act; | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-06T11:45:54-04:00 | |
| 3045555 | MR. H.R. BERT PENA 4c5c8c32-2649-4ca6-8698-ed2c5004d632 | Q3 | MR. H.R. BERT PENA | 400323519 | MARGO RX LLC(DBA RICHARD'S PHARMACY) | 2023 | third_quarter | PHA | PBM AND DRUG PRICES | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 0 | 0 | 2023-10-06T11:57:26-04:00 | ||
| 3045605 | FROST BROWN TODD LLC 116ceefa-cf61-413c-8351-7ea63ec0bd7e | Q3 | FROST BROWN TODD LLC | 283572 | DISPOSERX | 2023 | third_quarter | PHA | Support Act | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-10-06T13:26:13-04:00 | |
| 3045696 | REPUBLIC CONSULTING, LLC 01c099c1-1135-4f1c-9d07-87e8519d351e | Q3 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2023 | third_quarter | PHA | Monitor Health Data Policy. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-06T15:13:20-04:00 | |
| 3045796 | DENTONS US LLP ae59222c-bc9a-4499-9aab-f2641933d265 | Q3 | DENTONS US LLP | 36105 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA | 2023 | third_quarter | PHA | Federal issues impacting workforce and innovation in the pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-06T16:52:59-04:00 | |
| 3045950 | RED+BLUE STRATEGIES 5bda4cac-4e0b-4968-ac9a-e167f8c21c1d | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2023 | third_quarter | PHA | H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 2973 - Modernizing and Ensuring PBM Accountability Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2023-10-07T14:44:38-04:00 | |
| 3045986 | RED+BLUE STRATEGIES 83e66f82-0abf-48f4-96bc-6b3fd01a45d9 | Q3 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2023 | third_quarter | PHA | Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-07T16:03:52-04:00 | |
| 3046053 | HOLLAND & KNIGHT LLP a47e6d08-3b8a-4b0e-a669-7ca5ac6e57b9 | Q3 | HOLLAND & KNIGHT LLP | 18466 | VIATRIS INC | 2023 | third_quarter | PHA | Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-08T12:56:58-04:00 | |
| 3047104 | INDEPENDENT PHARMACY COOPERATIVE 3cc56634-7aba-4a80-993f-ea796bc5bb33 | Q3 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2023 | third_quarter | PHA | IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act | Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-10T17:22:04-04:00 | |
| 3047359 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 5af1da9d-ea6b-486c-8b19-b100437db149 | Q3 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2023 | third_quarter | PHA | H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542, the Delinking Revenue from Unfair Gouging Act; H.R. 5142, the Vaccine Injury Compensation Modernization Act of 2023; H.R. 5143, the Vaccine Access Improvement Act of 2023; S. 2305, the Biosimilar Red Tape Elimination Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 360000 | 0 | 0 | 2023-10-11T11:53:04-04:00 | |
| 3047414 | RAY ANDERSON 8ff4db64-5d60-4f74-8d1d-b065b1b3dc00 | Q3 | RAY ANDERSON | 401105487 | 340B HEALTH | 2023 | third_quarter | PHA | Contract Pharmacy-No legislation yet 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act (not yet introduced) 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA) | 15000 | 0 | 0 | 2023-10-11T13:01:47-04:00 | |
| 3047481 | PUBLIC CITIZEN 62687c95-b67d-403a-a220-a00b1d3c4d89 | Q3 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2023 | third_quarter | PHA | S.1476 Pharmaceutical Research Transparency Act, S.954 Affordable Insulin Now Act, Medicare drug price negotiation implementation; Bayh-Dole royalty-free rights and contractual reasonable pricing conditions, NDAA government owned medical invention licensing, research and development transparency, and other transactions authority justification, pay for delay reform; product hopping reform; citizen petition abuse reform; FDA prescription drug transparency, S.2220 PREVAIL Act; S. 79 Interagency Patent Coordination and Improvement Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, We PAID Act | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 75000 | 0 | 0 | 2023-10-11T14:31:22-04:00 | |
| 3047579 | KOUNTOUPES DENHAM CARR & REID, LLC 3902152f-a87d-41e2-8f73-0cf2b2706475 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ABBOTT LABORATORIES | 2023 | third_quarter | PHA | Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, the Equitable Community Access to Pharmacist Services Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-11T15:25:14-04:00 | |
| 3047618 | KOUNTOUPES DENHAM CARR & REID, LLC 983996fa-571c-4d57-87b0-49fb9f05e17e | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2023 | third_quarter | PHA | General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-11T15:42:53-04:00 | |
| 3047963 | LUNGREN LOPINA LLC ce8d4a13-8084-4954-8520-542e4e2cf800 | Q3 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2023 | third_quarter | PHA | Fair treatment for US based pharmaceutical ingredients | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-10-12T10:29:45-04:00 | |
| 3048469 | KOUNTOUPES DENHAM CARR & REID, LLC fa3d9820-cada-4428-bd69-3b09779a5cb2 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2023 | third_quarter | PHA | Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-12T16:34:48-04:00 | |
| 3048677 | BLUE SHIELD OF CALIFORNIA 07c7db17-f475-4bab-ac12-f4de0c14f7d8 | Q3 | BLUE SHIELD OF CALIFORNIA | 6518 | BLUE SHIELD OF CALIFORNIA | 2023 | third_quarter | PHA | Matters related to pharmacy benefit manager reform. | HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2023-10-12T19:39:27-04:00 | |
| 3048865 | WAKEFERN FOOD CORP. 2f185c71-1ab8-4983-ac49-6e5b83e233d8 | Q3 | WAKEFERN FOOD CORP. | 400588798 | WAKEFERN FOOD CORP. | 2023 | third_quarter | PHA | Protect Patient Access to Pharmacies Act (S. 2052) The measure addresses DIR/PBM reform, including: 1) Eliminating DIR fees 2) Establishing a rate floor for pharmacy reimbursements 3) Establishing standardized performance measures. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2023-10-13T10:50:06-04:00 | ||
| 3048871 | DAVE KOLBE CONSULTING e6676d64-1d7d-4289-96ed-72047cf137cf | Q3 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2023 | third_quarter | PHA | Inflation Reduction Act (IRA) - Opposing Expansion of IRA Bill's Drug Coverage. While understanding the intention to provide wider access to affordable medications, we believe this proposed expansion could have unintended negative consequences on employment with the prescription drug industry. Protecting Patients Against PBM Abuses Act (H.R. 2880) - Urging support of H.R. 2880. 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) - Oppose legislation to expand upon the recent bipartisan language in the draft to reintroduce the concept of "Reasonable Pricing" requirements. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-13T10:53:37-04:00 | |
| 3048908 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER b2a10fc0-ecf7-4693-8976-8d96b03a45cc | Q3 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2023 | third_quarter | PHA | 340B | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 36400 | 0 | 0 | 2023-10-13T11:09:16-04:00 | |
| 3049397 | BOLD STRATEGIES, LLC 52ea032f-f9be-437c-91cd-78252dfeef3a | Q3 | BOLD STRATEGIES, LLC | 401104653 | MORRIS & DICKSON CO., LLC | 2023 | third_quarter | PHA | Prescription drug issues generally. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-10-13T15:40:30-04:00 | |
| 3049770 | GOVERNMENT COUNSEL, LLC dd1ee305-4ebf-4537-b0e6-df59980b7308 | Q3 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2023 | third_quarter | PHA | H.R. 501-Block, Report, And Suspend Suspicious Shipments Act. Legislative proposals to prevent and respond to drug shortages. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-14T12:46:09-04:00 | |
| 3050056 | TRUSYNERGY f36e2a95-1caa-48dd-9c8a-1649fc69b2ea | Q3 | TRUSYNERGY | 401107715 | BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) | 2023 | third_quarter | PHA | Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-10-15T11:46:30-04:00 | |
| 3050332 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 6174e9c7-d6be-45ba-88fa-278e77cbf53a | Q3 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | MICHIGAN HEALTH & HOSPITAL ASSOCIATION | 2023 | third_quarter | PHA | Advised on FY 24 Labor-Health and Human Services-Education appropriations; H.R. 5378, Lower Cost, More Transparency Act; Medicare reimbursement; Medicaid coverage and Medicaid supplemental payments; health care workforce issues; Rural Emergency Hospital designation; cancer drug shortages; Centers for Medicare & Medicaid Services Minimum Staffing Standards for Long-Term Care Facilities proposed rule. Engaged with Michigan congressional delegation offices. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-15T23:48:37-04:00 | |
| 3050423 | ARNOLD & PORTER KAYE SCHOLER LLP 6a889214-5c9e-474f-9d06-d2e1680cf1e1 | Q3 | ARNOLD & PORTER KAYE SCHOLER LLP | 4301 | NOVO NORDISK, INC. | 2023 | third_quarter | PHA | Issues related to pharmacy benefit managers and the 340B Program. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-10-16T08:48:25-04:00 | |
| 3050608 | UNIVERSITY OF IOWA 2b7dba95-e15e-4572-9848-52fca1321b09 | Q3 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2023 | third_quarter | PHA | N/A | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-16T10:24:44-04:00 | |
| 3050745 | FAEGRE DRINKER BIDDLE & REATH LLP ddd212e9-c294-46de-8d4a-909999f57ec2 | Q3 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) | 2023 | third_quarter | PHA | Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act);S. 1843, H.R. 3429 - SHOPSAFE Act; S. 4858 - Cooper Davis Act. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-10-16T11:05:37-04:00 | |
| 3050802 | MCDERMOTT+ LLC 89333959-5d50-4ccd-8811-32d738cd996a | Q3 | MCDERMOTT+ LLC | 401103287 | CAMPAIGN FOR SUSTAINABLE DRUG PRICING | 2023 | third_quarter | PHA | Prescription drug pricing issues. Pricing of Covid 19 vaccines. H.R. 485 - the Protecting Health Care for All Patients Act. S. 775 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 935 - Fair Accountability and Innovative Research Drug Pricing Act of 2023. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-16T11:10:30-04:00 | |
| 3050930 | 4C COMMUNICATIONS, INC. ae831e18-63f7-4eff-a3fe-d441bbfd25f2 | Q3 | 4C COMMUNICATIONS, INC. | 323717 | HEALTHCARE LEADERSHIP COUNCIL | 2023 | third_quarter | PHA | Medicare Advantage, Healthcare Workers Resilience Act | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2023-10-16T11:55:06-04:00 | ||
| 3051088 | THE CONSILIO GROUP 8904d241-d9f5-4967-b4f0-9c70078d168c | Q3 | THE CONSILIO GROUP | 400374717 | PARATEK PHARMACEUTICALS | 2023 | third_quarter | PHA | Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use | Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office | 36000 | 0 | 0 | 2023-10-16T12:45:10-04:00 | |
| 3051195 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION b91e584b-6abd-491b-8cc3-03394642be77 | Q3 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2023 | third_quarter | PHA | Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, onshoring, and supply chains | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-16T13:45:09-04:00 | |
| 3051269 | LUPIN PHARMACEUTICALS INC d6fc32b1-4034-4db4-a080-7d9ba6ebd1da | Q3 | LUPIN PHARMACEUTICALS INC | 401104766 | LUPIN PHARMACEUTICALS INC | 2023 | third_quarter | PHA | Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal. | HOUSE OF REPRESENTATIVES,SENATE | 105000 | 0 | 0 | 2023-10-16T14:17:04-04:00 | |
| 3051354 | EMERGENT STRATEGIES ba42b329-7fd6-4868-9e1c-3b7e864a04a4 | Q3 | EMERGENT STRATEGIES | 401104778 | GENBIOPRO, INC. | 2023 | third_quarter | PHA | FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS). | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2023-10-16T14:54:23-04:00 | |
| 3051415 | BLUECROSS BLUESHIELD OF TENNESSEE 7ba744de-8fa8-4de1-a271-02af81d17a9d | Q3 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2023 | third_quarter | PHA | Insulin Act; Insulin Out of Pocket Charges; Pharmacy Benefit Managers; Delinking PBM language S 954 - Affordable Insulin Now Act A bill to provide for appropriate cost-sharing for insulin products covered under private health plans and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage S.127 - PBM Transparency Act of 2023 To prevent unfair and deceptive acts or practices and the dissemination of false information related to PBM services for Rx drugs, etc. | HOUSE OF REPRESENTATIVES,SENATE | 485000 | 0 | 0 | 2023-10-16T15:18:37-04:00 | |
| 3051638 | BROWNSTEIN HYATT FARBER SCHRECK, LLP b47cf11b-44bd-457e-927f-48711eec7427 | Q3 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | WALGREEN CO. | 2023 | third_quarter | PHA | Pharmacist provider status Issues related to drug pricing Implementation of the Inflation Reduction Act of 2022 Issues related to access and distribution of pharmaceutical products | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-16T16:24:58-04:00 | |
| 3052100 | KNIGHT CAPITOL CONSULTANTS 5bca2ba5-c5cf-4b6a-b650-db6e3c72864a | Q3 | KNIGHT CAPITOL CONSULTANTS | 40036301 | REGENXBIO | 2023 | third_quarter | PHA | Development of legislation that would affect the research, regulation or pricing of biopharmaceuticals, including implementation of the Inflation Reduction Act (no specific legislation) | SENATE | 60000 | 0 | 0 | 2023-10-16T22:53:51-04:00 | |
| 3052289 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 87f7cf1c-e63d-4922-a33f-c542dd7be56c | Q3 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2023 | third_quarter | PHA | OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 160780 | 0 | 0 | 2023-10-17T10:06:03-04:00 | |
| 3052396 | PANNONE LOPES DEVEREAUX & O'GARA LLC fef434ea-be7b-4226-b4e0-014ec99b8cca | Q3 | PANNONE LOPES DEVEREAUX & O'GARA LLC | 401105501 | AMGEN | 2023 | third_quarter | PHA | Prescription drug pricing. | 9000 | 0 | 0 | 2023-10-17T10:31:41-04:00 | ||
| 3052399 | ARENTFOX SCHIFF LLP 6d932d1c-058b-40fb-a9e3-1e3a0ed72057 | Q3 | ARENTFOX SCHIFF LLP | 4208 | AMERICAN PHARMACY COOPERATIVE, INC. | 2023 | third_quarter | PHA | Prescription drug pricing generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-17T10:33:05-04:00 | |
| 3052678 | ALB SOLUTIONS 5f454734-7cb5-4b62-9280-b12400148cea | Q3 | ALB SOLUTIONS | 401105973 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2023 | third_quarter | PHA | Issues related to regulatory and legislative developments regarding biosimilars. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-10-17T11:36:40-04:00 | |
| 3052680 | BUCHANAN INGERSOLL & ROONEY PC 0903192e-6775-4530-9df1-01c873205aa6 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | AIM IMMUNOTECH INC. | 2023 | third_quarter | PHA | Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-10-17T11:36:55-04:00 | |
| 3052771 | AMERICAN VETERINARY MEDICAL ASSOCIATION 204155bc-e423-440b-9f27-12b6847880ee | Q3 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2023 | third_quarter | PHA | H.R. 1418/ S. 1844 Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization H.R. 1839/S. 993 Combatting Illicit Xylazine Act H.R. 4531 SUPPORT Act Review of zootechnical animal food substances language as an amendment to the Animal Drug User Fee Amendments of 2023 H.R. 1683 Generic Animal Drug Advancement Act, all provisions | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 270000 | 0 | 0 | 2023-10-17T11:52:31-04:00 | |
| 3052827 | SHIONOGI INC. f2a58288-ab31-48ce-914f-d6bcf82a2b12 | Q3 | SHIONOGI INC. | 401107081 | SHIONOGI INC. | 2023 | third_quarter | PHA | Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355) | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2023-10-17T12:05:03-04:00 | |
| 3052933 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES 83fca7c6-8250-4ca6-b441-117a780f469c | Q3 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 26672 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2023 | third_quarter | PHA | H.R. 1613 Drug Price Transparency in Medicaid Act of 2023 H.R. 1770 The Equitable Community Access to Pharmacist Services Act H.R. 2880 Protecting Patients Against PBM Abuses Act H.R. 2816 The PBM Sunshine and Accountability Act H.R. 3561 The Patient Act H.R. 4365 Department of Defense Appropriations Act, 2024 H.R. 5378 Lower Costs More Transparency H.R. 5393 To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes. H.R. 5400 The Neighborhood Options for Patients Buying Medicines (NO PBMs) Act S. 113 Prescription Pricing for the People Act S. 127 Pharmacy Benefit Manager Transparency Act S. 1038 Drug Price Transparency in Medicaid Act of 2023 S. 1339 Pharmacy Benefit Manager Reform Act S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act S. 2052 Protect Patient Access to Pharmacies Act S. 2436 The Neighborhood Options for Patients Buying Medicines (NO PBMs) Act S. 2666 ECAPS 2.0 Act S. 2973 Modernizing & Ensuring PBM Accountability (MEPA) Act | HOUSE OF REPRESENTATIVES,SENATE | 370000 | 0 | 0 | 2023-10-17T12:27:17-04:00 | |
| 3053207 | TRAVERE THERAPEUTICS 48bf7db4-7129-4824-9060-760d422c1970 | Q3 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2023 | third_quarter | PHA | Legislation regarding drug pricing, value, and reimbursement including implementation of the Inflation Reduction Act of 2022. The Safe Step Act, H.R. 2630/S. 652. The HELP Copays Act, H.R. 830/S. 1375. H.R. 5339, the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 175000 | 0 | 0 | 2023-10-17T13:22:17-04:00 | |
| 3053375 | BROYDRICK & ASSOCIATES 3f4b0995-7a18-41b0-bffa-9385e81d4ed9 | Q3 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2023 | third_quarter | PHA | Funding for drug treatment for PTSD and COVID-19, BARDA appropriations. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-10-17T13:58:58-04:00 | |
| 3053517 | TWENTY-FIRST CENTURY GROUP, INC. e045eb76-196b-470f-96b0-10fda941b555 | Q3 | TWENTY-FIRST CENTURY GROUP, INC. | 38687 | CARDINAL HEALTH, INC. | 2023 | third_quarter | PHA | Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 24000 | 0 | 0 | 2023-10-17T14:35:23-04:00 | |
| 3054126 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 107c6ded-81e3-4036-8f1d-41324c7c0144 | Q3 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | ROMARK GLOBAL PHARMA, LLC | 2023 | third_quarter | PHA | Issues regarding Biomedical Advanced Research and Development Authority Covid-19 Therapeutics' Pandemic All Hazards Preparedness Act | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2023-10-17T17:00:59-04:00 | ||
| 3054592 | FORBES-TATE 5ac93b87-d323-4ffd-9cde-317345bdc6bf | Q3 | FORBES-TATE | 400976792 | PHRMA | 2023 | third_quarter | PHA | Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-10-17T20:04:06-04:00 | |
| 3054712 | PORT SIDE STRATEGIES, LLC 643867a9-3dec-44e5-b643-71dc56da589f | Q3 | PORT SIDE STRATEGIES, LLC | 401105394 | SOCIAL SECURITY WORKS | 2023 | third_quarter | PHA | Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-10-17T21:05:38-04:00 | |
| 3054717 | PORT SIDE STRATEGIES, LLC ac551ec4-8c32-48f5-a455-8727c7641269 | Q3 | PORT SIDE STRATEGIES, LLC | 401105394 | NEW VENTURE FUND | 2023 | third_quarter | PHA | Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S.2305 - Biosimilar Red Tape Elimination Act - in support. S. 2157 - A bill to repeal prescription drug price control provisions of the Inflation Reduction Act - opposed. H.R.4895 - Lowering Drug Costs for American Families Act - in support. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 0 | 0 | 2023-10-17T21:07:22-04:00 | ||
| 3054720 | PORT SIDE STRATEGIES, LLC 32c2a356-71ca-452a-bb3f-93e8b1060977 | Q3 | PORT SIDE STRATEGIES, LLC | 401105394 | CENTER FOR HEALTH AND DEMOCRACY | 2023 | third_quarter | PHA | Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. S.1339 - Pharmacy Benefit Manager Reform Act - in support. S.2973 - Modernizing and Ensuring PBM Accountability Act - in support. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-10-17T21:09:01-04:00 | |
| 3054786 | FORBES-TATE 6b0f7f1c-709f-4641-b2af-af57d41b5a8c | Q3 | FORBES-TATE | 400976792 | INDEPENDENT PHARMACY COOPERATIVE | 2023 | third_quarter | PHA | Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-17T21:23:06-04:00 | |
| 3054841 | HEALTHSPERIEN d18acc88-454f-4a57-99bf-1ea947681914 | Q3 | HEALTHSPERIEN | 401103150 | EXACT CARE PHARMACY | 2023 | third_quarter | PHA | Advocate for codifying definition for long-term care pharmacy. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-10-17T22:03:24-04:00 | |
| 3054976 | PATIENTS RISING NOW 1e754a03-ae98-49e7-84c7-108a5a779517 | Q3 | PATIENTS RISING NOW | 401107039 | PATIENTS RISING NOW | 2023 | third_quarter | PHA | Accelerated Approval. Pharmacy Benefits Managers. S.127 - Pharmacy Benefit Manager Transparency Act of 2023. Medical patents. Alternative Funding Vendors. H.R.2816 - PBM Sunshine and Accountability Act. H.R.2880 - Protecting Patients from PBM Abuses Act. H.R.3839 - Increasing Transparency in Generic Drug Applications Act. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-18T01:10:24-04:00 | |
| 3055121 | FORBES-TATE 485a3939-3a0e-4937-a70f-b9cf22cd077b | Q3 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2023 | third_quarter | PHA | Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-10-18T09:02:34-04:00 | |
| 3055279 | SQUIRE PATTON BOGGS c36f7b51-7514-4cda-ba46-5dc482d687a9 | Q3 | SQUIRE PATTON BOGGS | 30906 | SK HYNIX AMERICA, INC. | 2023 | third_quarter | PHA | Monitor proposals and issues related to biopharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 110000 | 0 | 0 | 2023-10-18T09:44:11-04:00 | |
| 3055532 | AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY cda689e5-8790-41fd-933a-96541dad16c7 | Q3 | AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY | 3402 | AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY | 2023 | third_quarter | PHA | compounding of bulk moxifloxacin | Food & Drug Administration (FDA) | 148478 | 0 | 0 | 2023-10-18T10:30:40-04:00 | |
| 3055657 | TARPLIN, DOWNS & YOUNG, LLC f7abb306-521c-4858-adda-0182fd281a7e | Q3 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2023 | third_quarter | PHA | Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 501 Halt, Block, and Suspend Suspicious Orders HR 1770 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 80000 | 0 | 0 | 2023-10-18T10:58:00-04:00 | |
| 3056325 | FAEGRE DRINKER BIDDLE & REATH LLP 4d53bbcf-3ffc-411b-a5e9-6e1c516fa223 | Q3 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | CIRCLE MEDICAL | 2023 | third_quarter | PHA | Issues related to telehealth/telemedicine and pharmacies. | 20000 | 0 | 0 | 2023-10-18T12:56:11-04:00 | ||
| 3056341 | WINNING STRATEGIES WASHINGTON 541f44a9-7d87-4c01-b5e9-d20cb48a35e3 | Q3 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2023 | third_quarter | PHA | Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-10-18T12:57:14-04:00 | |
| 3056683 | HARMONY BIOSCIENCES af6f1bc1-f26e-4bbb-afe1-d894b8ee2745 | Q3 | HARMONY BIOSCIENCES | 401105020 | HARMONY BIOSCIENCES | 2023 | third_quarter | PHA | Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications; H.R.1350, Camerons Law; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R. 1805, Leos Law; Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy; H.R. 830, S.1375, The HELP Copays Act; H.R. 5539, The ORPHAN Cures Act. | HOUSE OF REPRESENTATIVES,SENATE | 250000 | 0 | 0 | 2023-10-18T13:48:55-04:00 | |
| 3056846 | DESIMONE CONSULTING, LLC b68d21ab-9d98-476d-9ae5-104976e8eedf | Q3 | DESIMONE CONSULTING, LLC | 400931695 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2023 | third_quarter | PHA | Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-10-18T14:05:21-04:00 | |
| 3057548 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH f0bff0af-a21b-458b-90af-22a905b1841a | Q3 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2023 | third_quarter | PHA | Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Partnership for Part D Access coalition congressional meetings and signed coalition letter to CMS in response to Medicare Prescription Payment Plan Part One Guidance in support of continued protection for the six protected classes policy. Signed Medicare Access for Prescription Rx (MAPRx) coalition comment letter in response to Medicare Prescription Payment Plan Part One Guidance. Signed Alliance for Aging Research coalition letter in response to Medicare Prescription Payment Plan Part One Guidance in support of proposed beneficiary protections and to provide feedback on implementation considerations for the Medicare Prescription Payment Plan program. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2023-10-18T15:35:36-04:00 | |
| 3057566 | MASSACHUSETTS MEDICAL SOCIETY 6309ede5-4811-45a8-b90e-e9b71e12d3ae | Q3 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2023 | third_quarter | PHA | Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-10-18T15:36:58-04:00 | |
| 3057988 | BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. fb208931-9bac-47fd-877c-c34d8386efb0 | Q3 | BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. | 323876 | BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 2023 | third_quarter | PHA | Insulin Out of Pocket Charges; Finance PBNM Framework Proposals; Covid Vaccines S. 150 - Affordable Prescriptions for Patients Act of 2023 A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. John Cornyn (R-TX) S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 A bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. Sponsor: Sen. Maria Cantwell (D-WA) S.1067 - Ensuring Timely Access to Generics Act of 2023 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1114 - Expanding Access to Low-Cost Generics Act of 2023 To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S.1269 - INSULIN Act of 2023 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S.2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-10-18T16:39:04-04:00 | |
| 3058037 | NATIONAL RURAL HEALTH ASSOCATION 88e70eac-dcfe-48e2-88e9-72e34e46c680 | Q3 | NATIONAL RURAL HEALTH ASSOCATION | 53048 | NATIONAL RURAL HEALTH ASSOCATION | 2023 | third_quarter | PHA | Rural Health Care Policy and 340b Program | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 8591 | 0 | 0 | 2023-10-18T16:45:25-04:00 | |
| 3058112 | CAPITOL COUNSEL LLC cbe19398-cf0f-498a-9cf6-6646d4d90887 | Q3 | CAPITOL COUNSEL LLC | 313715 | EMD SERONO, INC. | 2023 | third_quarter | PHA | Issues regarding the availability and pricing of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-18T16:54:31-04:00 | |
| 3058267 | THORN RUN PARTNERS 73cc9c1a-74f4-4712-8754-76c870b85066 | Q3 | THORN RUN PARTNERS | 400534596 | AMERICAN POLICY VENTURES ACTION | 2023 | third_quarter | PHA | Issues and legislation related to reduction of prescription medication for Americans. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2023-10-18T17:15:57-04:00 | |
| 3058329 | WALGREEN COMPANY 8714f57d-1fe6-495e-8647-980c84d21fe8 | Q3 | WALGREEN COMPANY | 309071 | WALGREEN COMPANY | 2023 | third_quarter | PHA | H.R. 7213/S. 2477- Equitable Community Access to Pharmacist Services Act: Issues related to access to pharmacist services. Public Law: 109-148 - Public Readiness and Emergency Preparedness Act (PREP Act): Issues related to COVID testing and vaccinations. H.R. 2503/S. 1701 - NIH Clinical Trial Diversity: Issues related to NIH funding for programs to increase diversity in clinical trials. | HOUSE OF REPRESENTATIVES,SENATE | 940000 | 0 | 0 | 2023-10-18T17:22:56-04:00 | |
| 3058440 | HARPER DOWNING db041ea8-dad3-4d42-b250-3b467af0317e | Q3 | HARPER DOWNING | 401107879 | HUMANETICS CORPORATION | 2023 | third_quarter | PHA | Pandemic and All-Hazards Preparedness Act reauthorization | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-10-18T17:36:46-04:00 | |
| 3058546 | NELSON MULLINS RILEY & SCARBOROUGH 67964581-7c92-4526-8af0-c4b6201a8b74 | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | TIDELANDS HEALTH | 2023 | third_quarter | PHA | Issues related to the 340B Drug Pricing Program | SENATE | 40000 | 0 | 0 | 2023-10-18T17:56:57-04:00 | |
| 3058597 | INVARIANT LLC 76b9289a-8560-4aa3-8404-81d648af8ce2 | Q3 | INVARIANT LLC | 314237 | SK HYNIX AMERICA INC. | 2023 | third_quarter | PHA | Monitor proposals and issues related to biopharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2023-10-18T18:06:58-04:00 | |
| 3058629 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 1bd08551-ff3e-46e0-a98a-405a43ccd65a | Q3 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) | 401105192 | CVS HEALTH | 2023 | third_quarter | PHA | Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. | HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2023-10-18T18:20:31-04:00 | |
| 3058645 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 8868806b-6516-413a-90d6-edb2c00d8a0d | Q3 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | LILLY USA, LLC | 2023 | third_quarter | PHA | Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation | HOUSE OF REPRESENTATIVES | 60000 | 0 | 0 | 2023-10-18T18:27:59-04:00 | |
| 3058835 | E3 STRATEGIC CONSULTING GROUP 142398ed-3cc3-4a66-8a39-db360db2cae2 | Q3 | E3 STRATEGIC CONSULTING GROUP | 401104104 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2023 | third_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-10-18T20:19:19-04:00 | |
| 3058902 | POLARIS GOVERNMENT RELATIONS, LLC 688f18af-72e4-48b1-911f-797765350f14 | Q3 | POLARIS GOVERNMENT RELATIONS, LLC | 307730 | CIGNA CORPORATION | 2023 | third_quarter | PHA | Drug pricing and issues facing the pharmacy benefit manager industry generally | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2023-10-18T20:52:24-04:00 | |
| 3059099 | MASON STREET CONSULTING, LLC b62f6348-4984-4dec-bf72-be0464fe4751 | Q3 | MASON STREET CONSULTING, LLC | 401105150 | CAPITAL RX INC. | 2023 | third_quarter | PHA | PBM Reform. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-10-18T23:56:28-04:00 | |
| 3059165 | VAN SCOYOC ASSOCIATES ab7f72e9-d684-4c28-b9cd-bd4e77aabc17 | Q3 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2023 | third_quarter | PHA | H.R.2670/S.2226, National Defense Authorization Act for Fiscal Year 2024, Temperature monitoring technology S.2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2024, Temperature monitoring related issues | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-10-19T05:23:11-04:00 | |
| 3059421 | ELI LILLY AND COMPANY 9c6cfdbd-c193-4a1a-98fd-f20d7f9a9248 | Q3 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2023 | third_quarter | PHA | Hospital discounts; 340B program | HOUSE OF REPRESENTATIVES,SENATE | 2301360 | 0 | 0 | 2023-10-19T08:21:30-04:00 | |
| 3059670 | FAEGRE DRINKER BIDDLE & REATH LLP a928a3b3-8084-4fa1-b6b0-45fd48a2cd61 | Q3 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | VERDE ENVIRONMENTAL TECHNOLOGIES, INC. | 2023 | third_quarter | PHA | Drug safety. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 20000 | 0 | 0 | 2023-10-19T09:27:30-04:00 | |
| 3059736 | MARSHALL & POPP, LLC 94ba18df-c703-4d28-83cd-8eb48063afa8 | Q3 | MARSHALL & POPP, LLC | 401105121 | AMGEN USA INC. | 2023 | third_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-19T09:34:50-04:00 | |
| 3059819 | CHRISTIANACARE 0e531751-10fd-464d-b951-6984a826d187 | Q3 | CHRISTIANACARE | 401105790 | CHRISTIANACARE | 2023 | third_quarter | PHA | Issues related to the 340B Drug Discount Program Support for the Protect 340B Act of 2023 (H.R. 2534) | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2023-10-19T09:43:07-04:00 | ||
| 3059855 | MARSHALL & POPP, LLC 3cefa065-7ccb-4d4b-9ca0-e8108ea2e77c | Q3 | MARSHALL & POPP, LLC | 401105121 | GENENTECH, INC. | 2023 | third_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-19T09:48:22-04:00 | |
| 3059914 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 97ce6e5d-30ee-49bd-9b0e-d5666099a0c3 | Q3 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2023 | third_quarter | PHA | Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The PROTECT 340B Act (H.R. 2534), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to pharmacy residency funding (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 280000 | 0 | 0 | 2023-10-19T09:58:10-04:00 | |
| 3059919 | MARSHALL & POPP, LLC 01965ea4-b7f2-4932-9a7e-65a6ac2e5ac2 | Q3 | MARSHALL & POPP, LLC | 401105121 | PFIZER, INC. | 2023 | third_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-19T09:59:00-04:00 | |
| 3059933 | MARSHALL & POPP, LLC 7fa314ae-a743-43d7-b6b2-4430f798b248 | Q3 | MARSHALL & POPP, LLC | 401105121 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2023 | third_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-10-19T10:00:52-04:00 | |
| 3059945 | MARSHALL & POPP, LLC feaccfcc-3a6d-41c2-9135-3f1266cc328a | Q3 | MARSHALL & POPP, LLC | 401105121 | SANOFI U.S. SERVICES, INC. | 2023 | third_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-10-19T10:01:48-04:00 | |
| 3060416 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6d96ffd8-fb59-475f-8578-ff22e7905366 | Q3 | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 6382 | BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 2023 | third_quarter | PHA | Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin. S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 120000 | 0 | 0 | 2023-10-19T11:07:14-04:00 | |
| 3060451 | FAEGRE DRINKER BIDDLE & REATH LLP 5976583d-6800-46cf-aa1f-cd9db21385bd | Q3 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | NATIONAL ASSOCIATION OF BOARDS OF PHARMACY | 2023 | third_quarter | PHA | Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth. | Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 40000 | 0 | 0 | 2023-10-19T11:09:30-04:00 | |
| 3060486 | GUIDEWELL MUTUAL HOLDING CORPORATION 3b30212e-e9a5-41f2-91d0-fe283e7ea7db | Q3 | GUIDEWELL MUTUAL HOLDING CORPORATION | 401103191 | GUIDEWELL MUTUAL HOLDING CORPORATION | 2023 | third_quarter | PHA | Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin. S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 0 | 0 | 2023-10-19T11:12:19-04:00 | ||
| 3060522 | FOLEY & LARDNER LLP df288bd3-0d61-4dd2-a4c0-f7c14b8c023f | Q3 | FOLEY & LARDNER LLP | 15042 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2023 | third_quarter | PHA | Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-10-19T11:15:58-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);